Our newsmaker this hour, Dr. . Marty McCary, the FDA commissioner, marking his first 100 days on the job. It's been a busy few months with many changes at the agency from vaccines to staffing.Good morning, uh, doctor. Good morning, Joe. I don't maybe you've been on a few time.I don't I I don't remember, but we all went through uh that that period together, obviously, and and there's a lot of u of of a look back now at at at that period. you know, it's, you know, it's a it's a hot button issue and sometimes ...

The DOJ may be releasing the list of Jeffrey Epstein's clients. Will that really happen. It's sitting on my desk right now to review.Um, that's been a directive um by President Trump. I'm reviewing that. That was Attorney General Pam Bondi in February of this year saying she had the client list of convicted sex offender Jeffrey Epstein quote on her desk.But that comment now clashes with a report this week from the DOJ and FBI which stated there was no client list and Epstein did not blackmail the people who ...

[Music] Right. Before I begin my presentation, quick show of hands. How many of you have followed an order in the past 24 hours. Hands up if you have followed any sort of order.Right. Hands down. Now take a moment to think what was the order.I have a shocking statistic for you all today that reveals some disturbing nature about humans. Did you know that 65% people were willing to shock a stranger. That came from Mgrim's 1963 experiment.It was considered controversial as he studied how ordinary people would ...

The state believes that its evidence would then show that um the defendant entered the residence of 11:22 through the kitchen sliding door on the back side of the residence, which is the side of the residence that would uh face the area above where the defendant's car was parked. Defendant entered the residence, went to the third floor, and with a knife killed Madison Mogan and Caitlyn Gonzalez. The defendant as he left that room for whatever reason ended up leaving or the sheath for a KBAR knife was left o ...

Brian Cobberger appears to have struck a plea deal with prosecutors in the case of the Idaho college murders. Cobberger accused in the 2022 killings of four University of Idaho students at their off-campus home. Authorities arresting him at his parents home in Pennsylvania weeks after their the deaths the killings.This possible resolution coming just weeks before Cobberger's trial was set to begin. Prosecutors were seeking the death penalty. should he have been convicted.But we're hearing from one victim's ...

The Stories Crimes Tell: Listening Beyond the Evidence explores Jon’s experience as a detective who uncovered hidden narratives through the art of listening—not just to words, but to silence, body language, and emotion. Evidence can reveal the what, but only listening uncovers the why. A confession may confirm guilt, but the hesitation, the shift in tone, or the unspoken fear reveals the deeper truth. Through years of interviewing victims, witnesses, and suspects, Jon learned that his most powerful tools we ...

Manfred Stapff's Breakthrough Book Hits #1 on Amazon, Tackles Misinformation with Real-World EvidenceJune 05, 2025 2:00 PM EDT | Source: Avazona Ltd.Summary: Dr. Manfred Stapff's newly released book, Real-World Evidence Unveiled: Navigating the Maze of Modern Misinformation, has soared to #1 on Amazon in multiple categories. New York, New York--(Newsfile Corp. - June 5, 2025) - Candid-Advisory founder and renowned physician-scientist Dr. Manfred Stapff has made a notable impact in the publishi ...

CareDx (CDNA) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Good morning. I'm John Hanna, the president and CEO at CareDx. Thank you all for joining us today. This is our safe harbor statement. We may make forward looking statements during the presentation. Please refer to the safe harbor on our website. At CareDx we've built an experienced leadership team in the molecular diagnostics market to drive profitable growth. We have six fifty employees globally, 180 driving our commercial growth in the marke ...

Summary of IQVIA (IQV) 2025 Conference Call Company Overview - **Company**: IQVIA (IQV) - **Industry**: Life Sciences Tools and Diagnostics Key Financial Highlights - **Q1 Performance**: Revenue exceeded the high end of guidance, EBITDA was above the midpoint, and EPS was at the high end of guidance [3][4] - **TAS Growth**: TAS experienced over 7.6% growth at constant currency [3] - **Cash Flow**: Cash flow increased by 13% year-over-year, representing 89% of adjusted net income, which is at the high end of forecasts [4] - **Revenue Guidance**: Revenue guidance was raised by $275 million, primarily due to foreign exchange (FX) impacts [4] - **Bookings**: Book-to-bill ratio was 1.02, with a noted slowdown in decision-making and an increase in the time between RFPs and awards by about 10% [5][6] Industry Dynamics - **Emerging Biopharma vs. Large Pharma**: Emerging biopharma is experiencing a slowdown in funding, while large pharma is facing delays in decision-making due to uncertainty from recent government actions [8][9] - **Funding Environment**: The funding environment for biotech has been weak year-to-date, impacting order placements and decision-making [10][11] - **Regulatory Environment**: Concerns regarding agency changes, tariffs, and pricing actions are affecting large pharma's decision-making processes [13][14][17] Market Trends - **Real World Evidence (RWE)**: Growth in RWE is driven by the introduction of new drugs and increased scrutiny from payers for evidence of effectiveness [29][32] - **TAS Business**: The TAS segment is expected to continue its recovery, supported by new drug approvals and the need for commercialization support [22][23][26] Competitive Landscape - **Pricing Pressure**: Increased competition has led to pricing pressures, particularly in the FSP business, but management is focused on offsetting this with cost reductions [40][41] - **Market Dynamics**: Smaller CROs are feeling more pressure for business, which may lead to increased pricing competition [42] Margin and Growth Outlook - **Margin Projections**: Adjusted EBITDA margin is projected to contract by 20 basis points due to FX impacts, but long-term margin growth is expected to remain stable [45][49] - **Revenue Growth Expectations**: Anticipated constant currency revenue growth of 6-9% annually, driven by pharma spending, market share expansion, outsourcing, and M&A [49][50] Capital Deployment Strategy - **M&A and Share Repurchase**: The company is focused on M&A and share repurchase, with a preference for M&A opportunities that enhance growth capabilities [51][54] - **Debt Management**: Comfortable with current debt levels, with a net leverage ratio between 3.3 and 3.5 [52] Underappreciated Aspects - **Business Model**: IQVIA is not a pure CRO; its TAS business represents 40% of operations, which is often overlooked in comparisons with CRO peers [57][58] This summary encapsulates the key points discussed during the IQVIA conference call, highlighting the company's financial performance, industry dynamics, market trends, competitive landscape, margin outlook, capital deployment strategy, and aspects of the business that may be underappreciated.

Financial Data and Key Metrics Changes - For the first quarter of 2025, revenues were $651.3 million, a decline of 1.6% year-over-year, primarily due to varying late-stage clinical service fee wins and a slowing backlog burn rate [32][33] - Adjusted EBITDA for the quarter was $30.3 million, compared to $27.1 million in the prior year period, indicating year-over-year growth [32][37] - The net loss for the first quarter was $562.9 million, significantly higher than the net loss of $79.8 million in the prior year, mainly due to a goodwill impairment charge of $488.8 million [38][39] - The book-to-bill ratio for the quarter was 1.02 times, with a trailing twelve-month ratio of 1.14 times [6][37] - The backlog grew by 4% over the past twelve months, totaling over $7.7 billion [37] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increases in service fee and pass-through revenues, contributing positively to overall performance [33][37] - The company is experiencing a shift towards biotech, with a solid pipeline of opportunities, although some biotech customers are being more cautious due to funding concerns [10][11][46] - The full-service outsourcing business has shown success, with notable achievements such as completing recruitment for a renal product ahead of schedule and accelerating timelines for cancer studies [19][45] Market Data and Key Metrics Changes - The market environment remains competitive but stable, with larger customers maintaining consistent opportunities and spending [10][46] - There is a noted increase in caution among biotech customers regarding funding and regulatory confirmations, which is impacting decision-making timelines [11][90] - The pricing environment is competitive, but there is no notable lack of discipline around pricing [76] Company Strategy and Development Direction - The company is focused on improving customer relationships and enhancing its commercial strategy, including the incorporation of AI to increase efficiency [15][26] - A transformation year is anticipated for 2025, with goals to improve gross margins and reduce SG&A costs [16][48] - The company aims to achieve a 1.2 times book-to-bill ratio over time, although current economic uncertainties make it difficult to predict new business wins [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience and ability to navigate challenges, emphasizing the importance of innovation in drug development [12][51] - The company is targeting operating cash flow to be positive for the remainder of 2025, driven by improving DSO and adjusted EBITDA [41][86] - There is an expectation for SG&A improvements to be more pronounced in the latter half of the year as efficiency programs take effect [80] Other Important Information - The company has reduced its permanent headcount by over 8% in the past year to align costs with revenue [34][48] - A significant goodwill impairment charge was recorded due to uncertain macroeconomic conditions and a decline in share price [38] - The company has initiated transformation programs to reduce personnel costs and optimize operational expenditures [48][50] Q&A Session Summary Question: Revenue expectations and cadence - The first quarter revenue was better than expected, but guidance suggests revenue may be flat to down for the rest of the year, with margin expansion expected to be gradual [58][64] Question: Clinical pharmacology RFP volume and win rates - The clinical pharmacology business remains strong, with a return of the pipeline, and efforts are being made to convert pass-through work into revenue [67][68] Question: Bookings backdrop and competition - The biotech pipeline is growing, but there is increased caution regarding funding and decision-making timelines, with competition remaining disciplined in pricing [70][76] Question: SG&A expectations - Marginal improvement in SG&A is expected in the second quarter, with more significant improvements anticipated in the latter half of the year [78][80] Question: Cash flow improvement and DSO expectations - DSOs are expected to improve over the year, targeting low to mid-40s by year-end, with cash flow expected to be positive in Q3 and Q4 [85][86] Question: Biotech funding concerns - There is caution among biotech customers regarding funding, leading to slower decision-making, but the pipeline remains strong [90][92]